Genevieve Boland, MD
Surgical Oncology · Boston, MANPI 1699801019
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $41,125 of the $53,464 with a category attached, or 76.9%. Merck accounts for 66.0% of it on its own, with 5 other manufacturers making up the rest. Among surgical oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $1406.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$35K
- Iovance Biotherapeutics, Inc.$10K
- Novartis$8K
- AstraZeneca$132
- Organogenesis Inc.$125
- E.r. Squibb & Sons, L.L.C.$100
What the payments were for
- Consulting fees$41,12577%
- Travel & lodging$11,29221%
- Food & beverage$1,0472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $35,309 |
| Iovance Biotherapeutics, Inc. | 12 | $10,001 |
| Novartis | 5 | $7,797 |
| AstraZeneca | 1 | $132 |
| Organogenesis Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Amtagvi$9,667
- MEKINIST$2,200
- TAFINLAR$2,200
- PURAPLY WOUND MATRIX$125
How this compares
$53,464 in reported general payments places this provider in the 95th percentile of 55 surgical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Boston
- Thanh BarbieBoston$108K
- Elizabeth MittendorfBoston$73K
- Eduardo Vega PizarroBoston$46K
- Monica Valero CamachoBoston$30K
- Jiping WangBoston$14K
- Arthur MoserBoston$12K
- Katherina CalvilloBoston$5K
- Teviah SachsBoston$5K
- Motaz QadanBoston$4K
- Nicole Look-HongBoston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.